GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Net Change in Cash

Cyteir Therapeutics (Cyteir Therapeutics) Net Change in Cash : $-24.64 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Cyteir Therapeutics's Net Change in Cash for the three months ended in Sep. 2023 was $-4.39 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 was $-24.64 Mil.

Cyteir Therapeutics Net Change in Cash Historical Data

The historical data trend for Cyteir Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics Net Change in Cash Chart

Cyteir Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Change in Cash
19.20 -17.96 178.79 -42.60

Cyteir Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.51 -6.77 -9.91 -3.57 -4.39

Cyteir Therapeutics Net Change in Cash Calculation

Cyteir Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-42.532+-0.312+0.242+0
=-42.60

Cyteir Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.556+0+0.164+0
=-4.39

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyteir Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Net Change in Cash
Comparable Companies
GOSS NYMXF ABOS AADI AAGH CDT GLSI SGMO VOR ACRV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Website
https://www.cyteir.com
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness officer: General Counsel C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey director C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong director 69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven 10 percent owner BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421

Cyteir Therapeutics (Cyteir Therapeutics) Headlines

From GuruFocus

Cyteir Therapeutics Names Adam Veness General Counsel

By Business Wire Business Wire • 04-25-2022

Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

By Business Wire Business Wire • 03-09-2022

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

By Business Wire Business Wire • 09-01-2021

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

By Business Wire Business Wire • 06-05-2022

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

By Business Wire Business Wire • 05-03-2022

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

By Business Wire Business Wire • 08-08-2022

Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors

By Business Wire Business Wire • 12-16-2021

Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

By Business Wire Business Wire • 11-01-2021

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

By Business Wire • 10-12-2023

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

By Business Wire Business Wire • 06-03-2023